{ "company": "Exact Sciences", "ticker": "EXAS", "period": { "from": "2026-02-26", "to": "2026-03-28", "days": 30 }, "sentiment_breakdown": { "positive": 34, "negative": 37, "neutral": 41 }, "synthesis": { "executive_summary": "**Executive Summary: Exact Sciences (EXAS) Sentiment Analysis**\n\nSentiment analysis for Exact Sciences (EXAS) during the period of February 26 to March 28, 2026, reveals a predominantly neutral market perception with a slight negative tilt. Out of 112 monitored items, neutral mentions comprised the largest share at 41 (36.6%), closely followed by negative sentiment at 37 (33.0%), and positive sentiment at 34 (30.3%). This distribution suggests a balanced but cautious market discourse, with no strong directional consensus emerging from the aggregated data.\n\nKey positive drivers included Exact Sciences' recognition with the Gallup Exceptional Workplace Award for the third consecutive year, highlighting strong employee engagement and a positive corporate culture. Conversely, a significant negative event, as classified by our sentiment model, was the announcement of a successful colorectal cancer screening program involving Exact Sciences' Cologuard test. While the program achieved an 84% screening rate, the associated sentiment was recorded as negative, indicating potential underlying concerns or specific contextual interpretations by the analysis model. Other identified sentiment items were largely unrelated to EXAS's core business operations.", "key_findings": [ "✓ Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year", "✓ Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year", "✓ Anthropogenic forcing of gully sidewall erosion: balancing natural susceptibility and land use management in areas with Cuestas relief under tropical climate dynamics in southeastern Brazil.", "✗ Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration", "✗ Villains that were defeated by being given exactly what they wanted", "✗ In Reign of Fire (2002) dragons awaken and emerge from underground, procreate, and almost wipe out all of humanity………..uh guys, did you not have fighter jets, warships, tanks etc. these aren’t magical Smaug dragons, there just flying reptiles that breathe fire. How exactly did we lose?" ], "overall_sentiment": "mixed" }, "top_positive": [ { "title": "Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year", "date": "2026-03-04", "source": "alpha_vantage", "score": 0.834 }, { "title": "Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year", "date": "2026-03-03", "source": "alpha_vantage", "score": 0.834 }, { "title": "Anthropogenic forcing of gully sidewall erosion: balancing natural susceptibility and land use management in areas with Cuestas relief under tropical climate dynamics in southeastern Brazil.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.772 }, { "title": "Trump: If Iran doesn’t FULLY OPEN, WITHOUT THREAT, the Strait of Hormuz, within 48 HOURS from this exact point in time, the United States of America will hit and obliterate their various POWER PLANTS, STARTING WITH THE BIGGEST ONE FIRST! Thank you for your attention to this matter. President DONALD", "date": "2026-03-22", "source": "reddit", "score": 0.724 }, { "title": "Scan, Screen, Support-A Digital Pathway for Assessing Supportive Care Needs in Oncology: Implementation Study.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.66 }, { "title": "The way it receives the red fruit, lightly tosses it, and then picks it up again is exactly like a human movement. 😂", "date": "2026-03-24", "source": "reddit", "score": 0.66 }, { "title": "CSLLY or EXAS: Which Is the Better Value Stock Right Now?", "date": "2026-03-04", "source": "alpha_vantage", "score": 0.649 }, { "title": "Engineering a Stable Grb2 Monomer: The W60A Mutation Disrupts Dimerization but Preserves Structural Integrity.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.612 }, { "title": "Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp.", "date": "2026-03-15", "source": "alpha_vantage", "score": 0.572 }, { "title": "Exact Sciences EHR Outreach Program Highlights Cologuard Growth And Valuation Debate", "date": "2026-03-07", "source": "alpha_vantage", "score": 0.572 } ], "top_negative": [ { "title": "Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration", "date": "2026-03-04", "source": "alpha_vantage", "score": -0.869 }, { "title": "Villains that were defeated by being given exactly what they wanted", "date": "2026-03-04", "source": "reddit", "score": -0.818 }, { "title": "In Reign of Fire (2002) dragons awaken and emerge from underground, procreate, and almost wipe out all of humanity………..uh guys, did you not have fighter jets, warships, tanks etc. these aren’t magical Smaug dragons, there just flying reptiles that breathe fire. How exactly did we lose?", "date": "2026-03-24", "source": "reddit", "score": -0.815 }, { "title": "Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.791 }, { "title": "Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.784 }, { "title": "Integrating Generative AI into Nomograms for Breast Cancer Nodal Risk Predictions.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.758 }, { "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.751 }, { "title": "A video of a Russian woman being beaten in Thailand has surfaced online - the footage shows her attacking first. The exact date the video was filmed is still unknown.", "date": "2026-03-20", "source": "reddit", "score": -0.7 }, { "title": "Privia Health Screening Program Increases Colorectal Cancer Screening Rates", "date": "2026-03-14", "source": "alpha_vantage", "score": -0.66 }, { "title": "Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 112, "items": [ { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-23", "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-20", "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526116862/0001193125-26-116862-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789", "date": "2026-03-26", "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leadership in cancer screening with Cologuard. The company, which generated $3.25 billion in revenue last year, faces challenges from competition and reimbursement pressures but is pursuing growth through advancements in multi-cancer detection tests. US investors are monitoring EXAS for its potential in early detection markets and its stable financial health, though risks", "sentiment_score": 0.274103, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789", "date": "2026-03-26", "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leading position in cancer screening diagnostics with products like Cologuard. Investors are closely watching its ability to navigate reimbursement challenges and advance its pipeline, especially in multi-cancer early detection tests. The company's strong capital structure and focus on growth in the preventive healthcare market make it a key player for US investors seekin", "sentiment_score": 0.031748, "sentiment_label": "Neutral", "relevance_score": 0.317456, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist", "url": "https://www.tradingview.com/news/tradingview:063a6549e37bf:0-key-facts-abbott-buys-exact-sciences-notes-settle-105-nasdaq-delist/", "date": "2026-03-23", "summary": "Exact Sciences has amended the terms for its convertible notes, with conversions now cash-settled at $105.00 per share, effective March 23, 2026. Following Abbott Laboratories' acquisition of Exact Sciences, the company completed its merger, requested Nasdaq delisting, and plans to suspend SEC reporting.", "sentiment_score": -0.438973, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026", "url": "https://www.minichart.com.sg/2026/03/23/exact-sciences-corp-exas-files-8-k-announcing-material-agreements-amendments-and-supplemental-indentures-march-2026/", "date": "2026-03-23", "summary": "Exact Sciences Corporation (EXAS) has completed its acquisition by Abbott Laboratories on March 23, 2026, as announced in an 8-K filing. Consequently, Exact Sciences is now a wholly-owned subsidiary of Abbott, and its common stock has been halted from trading and will be delisted from Nasdaq. Shareholders will receive the specified merger consideration, and the company will cease its SEC reporting obligations as an independent entity.", "sentiment_score": 0.028024, "sentiment_label": "Neutral", "relevance_score": 0.320107, "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "Abbott completes Exact Sciences acquisition", "url": "https://www.massdevice.com/abbott-completes-exact-sciences-acquisition/", "date": "2026-03-23", "summary": "Abbott has finalized its acquisition of cancer diagnostics developer Exact Sciences for $21 million, following a November 2025 agreement. This acquisition positions Abbott as a leader in cancer screening and diagnostics, integrating Exact Sciences' products like Cologuard, Oncotype Dx, Cancerguard, and Oncodetect. The deal is projected to add approximately $3 billion in incremental sales for Abbott in 2026.", "sentiment_score": 0.415985, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening", "url": "https://intellectia.ai/news/stock/abbott-acquires-exact-sciences-strengthening-leadership-in-cancer-screening", "date": "2026-03-23", "summary": "Abbott has completed its acquisition of Exact Sciences on March 20, 2026, positioning itself as a leader in the rapidly expanding cancer screening and diagnostics market, projected to be a $60 billion industry in the U.S. This strategic move adds market-leading products like Cologuard® and Oncotype DX® to Abbott's portfolio, enhancing its offerings for early cancer detection and personalized treatment. The acquisition is expected to boost Abbott's growth, strengthen its competitive edge, and dri", "sentiment_score": 0.017398, "sentiment_label": "Neutral", "relevance_score": 0.304515, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing", "url": "https://www.tradingview.com/news/tradingview:9f617a00194da:0-exact-sciences-announced-transfer-or-voluntary-withdrawal-of-listing/", "date": "2026-03-23", "summary": "Exact Sciences (EXAS) announced that its merger has been completed and, as a result, informed Nasdaq of its request to delist and deregister its common stock. Trading of EXAS stock was halted before the market open on March 23, 2026, and the company plans to file Form 15 to suspend SEC reporting obligations. This announcement follows an SEC filing dated March 23, 2026.", "sentiment_score": -0.642477, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-analyst-scrutiny-amid-moderate-buy/68964225", "date": "2026-03-23", "summary": "Exact Sciences Corp. (ISIN: US30063P1057) is currently facing analyst scrutiny, maintaining a \"Moderate Buy\" consensus from 24 analysts with an average price target of $69.90. The stock, trading around $64.64 USD on NASDAQ, is supported by its Cologuard and Oncotype DX portfolios, driving revenue growth in cancer screening. The company is actively pursuing expansion into European markets, which is attracting interest from DACH region investors due to rising healthcare spending in Germany and Swi", "sentiment_score": 0.495726, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following", "date": "2026-03-21", "summary": "Walgreens has partnered with Exact Sciences for a nationwide rollout of the Cologuard colorectal cancer screening test through its pharmacies, which could significantly impact Exact Sciences' growth. While this expansion addresses care gaps and diversifies screening access, investors should also consider Exact Sciences' historical cash burn and dependence on Cologuard, despite new data on its Oncodetect and Cancerguard tests. The company's investment narrative projects substantial revenue and ea", "sentiment_score": 0.321137, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences (NASDAQ: EXAS) secures approvals as Abbott merger targets March 23 close", "url": "https://www.stocktitan.net/sec-filings/EXAS/8-k-exact-sciences-corp-reports-material-event-84457867e21f.html", "date": "2026-03-21", "summary": "Exact Sciences has announced that all regulatory approvals and clearances for its merger with Abbott Laboratories have been obtained. Stockholders previously approved the transaction on February 20, 2026, and the merger is now anticipated to close on March 23, 2026, subject to the satisfaction or waiver of remaining conditions. Exact Sciences will become a wholly-owned subsidiary of Abbott upon completion of the merger.", "sentiment_score": 0.276204, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Abbott to close $21B Exact Sciences acquisition Monday", "url": "https://www.medtechdive.com/news/abbott-to-close-21b-exact-sciences-acquisition-monday/815315/", "date": "2026-03-20", "summary": "Abbott is set to finalize its $21 billion acquisition of Exact Sciences on Monday, having received all necessary regulatory clearances. This strategic move is expected to significantly bolster Abbott's presence in cancer screening and diagnostics, adding a new platform and an estimated $3 billion in incremental sales by 2026. Exact Sciences is known for its Cologuard test and other molecular cancer detection technologies, which Abbott anticipates will help reach millions more people for early ca", "sentiment_score": 0.452145, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Exact Sciences to be acquired by Abbott after receiving all regulatory approvals; closing anticipated March 23, 2026", "url": "https://www.tradingview.com/news/tradingview:a22546d93f58a:0-exact-sciences-to-be-acquired-by-abbott-after-receiving-all-regulatory-approvals-closing-anticipated-march-23-2026/", "date": "2026-03-20", "summary": "Exact Sciences announced that all regulatory approvals for its merger with Abbott have been received, with the transaction expected to close on March 23, 2026. This merger will make Exact Sciences a direct, wholly owned subsidiary of Abbott, following shareholder approval and regulatory clearance obtained on March 19, 2026. The closing is subject to remaining conditions and customary risks.", "sentiment_score": 0.442293, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Health care again among the state’s biggest M&A deals of the past year", "url": "https://biztimes.com/health-care-again-among-the-states-biggest-ma-deals-of-the-past-year/?amp=1", "date": "2026-03-18", "summary": "For the third consecutive year, a healthcare-focused company deal is among Wisconsin's largest mergers and acquisitions. Exact Sciences, based in Madison, was acquired by Illinois-based Abbott Laboratories for $21 billion in November. This acquisition follows other significant healthcare M&A deals in the state and notable acquisitions by Modine and several other Wisconsin-based companies across various sectors.", "sentiment_score": 0.420963, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "EXACT Sciences Corp. Hits New 52-Week High at $104.00", "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corp-hits-new-52-week-high-at-10400-3899129", "date": "2026-03-18", "summary": "EXACT Sciences Corp. (EXAS) has achieved a new 52-week high of $104.00, marking a significant 142.34% appreciation over the past year, far outpacing the S&P 500. The company, a mid-cap player in pharmaceuticals and biotechnology with a market capitalization of $19.8 billion, shows a manageable debt-to-equity ratio despite being a loss-making entity with a negative return on equity. This price movement highlights strong investor sentiment and dynamic market activity for the stock.", "sentiment_score": 0.496009, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026", "url": "https://www.businesswire.com/news/home/20260317158639/en/Exact-Sciences-to-Present-New-Molecular-Residual-Disease-and-Multi-Cancer-Early-Detection-Data-at-AACR-2026", "date": "2026-03-17", "summary": "Exact Sciences Corp. announced it will present new data on molecular residual disease (MRD) testing and multi-cancer early detection (MCED) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will highlight findings from the Oncodetect® test in triple-negative breast cancer and updated performance for the Cancerguard® test, reinforcing the company's strategy to detect cancer earlier and monitor disease post-treatment. These results showcase advancements ", "sentiment_score": 0.435318, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "EXACT Sciences Corp. Hits New 52-Week High at $103.92", "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corp-hits-new-52-week-high-at-10392-3897175", "date": "2026-03-17", "summary": "EXACT Sciences Corp. reached a new 52-week high of $103.92, demonstrating strong performance in the Pharmaceuticals & Biotechnology sector with a 142.13% stock price increase over the last year. Despite being a loss-making entity, the company maintains a manageable debt-to-equity ratio of 0.58 and a market capitalization of approximately $19.74 billion, with investors focusing on capital appreciation due to no dividend yield.", "sentiment_score": 0.435893, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval", "url": "https://www.msn.com/en-us/money/markets/exact-sciences-exas-merger-with-abbott-moving-forward-after-shareholder-approval/ar-AA1Xe0H5?ocid=TobArticle&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-17", "summary": "This article reports on the merger between Exact Sciences (EXAS) and Abbott (ABT) moving forward after Exact Sciences shareholders approved the deal. The acquisition will allow Exact Sciences to expand its cancer diagnostic products into new markets and leverage Abbott's global presence. The approval marks a significant step towards the completion of the merger.", "sentiment_score": 0.489433, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Jain Global LLC Purchases Shares of 481,607 Exact Sciences Corporation $EXAS", "url": "https://www.marketbeat.com/instant-alerts/filing-jain-global-llc-purchases-shares-of-481607-exact-sciences-corporation-exas-2026-03-16/", "date": "2026-03-16", "summary": "Jain Global LLC has acquired a significant new position in Exact Sciences (NASDAQ:EXAS), purchasing 481,607 shares valued at approximately $26.35 million. Other institutional investors like Holocene Advisors and Fred Alger Management also increased their stakes, bringing total institutional ownership to about 88.82%. Despite the increased institutional interest, analysts maintain a cautious outlook, with an average \"Reduce\" rating and a consensus target price of $92.13, even as the stock trades ", "sentiment_score": -0.229948, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corp Stock (ISIN: US30063P1057) Attracts Major Investors Amid Cancer Screening Moment", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-isin-us30063p1057-attracts-major-investors/68686842", "date": "2026-03-15", "summary": "Exact Sciences Corp. (EXAS) is attracting significant institutional investment, with firms like Bamco Inc. NY increasing their stakes, signaling strong confidence in its colorectal cancer screening leadership. Despite broader healthcare sector pressures and economic uncertainties, investors are drawn to the company's growth trajectory, its flagship Cologuard test, and its potential in preventive oncology, positioning EXAS for a potential rebound. European and DACH region investors are also showi", "sentiment_score": 0.403309, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.452, "confidence": 0.45 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp.", "url": "https://www.marketbeat.com/instant-alerts/filing-exact-sciences-corporation-exas-shares-purchased-by-efg-asset-management-americas-corp-2026-03-15/", "date": "2026-03-15", "summary": "EFG Asset Management Americas Corp. significantly increased its stake in Exact Sciences (NASDAQ:EXAS) by 60% in Q3, acquiring 13,910 additional shares, bringing its total to 37,109 shares valued at approximately $2.03 million. This increase in institutional ownership comes despite several analysts recently downgrading EXAS to \"Hold\" or \"Neutral,\" with an average \"Reduce\" rating and a target price of $92.13. The company also missed quarterly EPS expectations, reporting $(0.21) against a $0.08 est", "sentiment_score": -0.229524, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval", "url": "http://www.msn.com/en-us/money/markets/exact-sciences-exas-merger-with-abbott-moving-forward-after-shareholder-approval/ar-AA1Xe0H5?ocid=TobArticle&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-15", "summary": "The article reports that the proposed merger between Exact Sciences (EXAS) and Abbott is progressing well, following key approval from shareholders. This development signifies a major step towards the completion of the acquisition, indicating that the deal is on track to close as planned.", "sentiment_score": 0.433275, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Privia Health Screening Program Increases Colorectal Cancer Screening Rates", "url": "https://www.mychesco.com/a/news/regional/privia-health-screening-program-increases-colorectal-cancer-screening-rates/", "date": "2026-03-14", "summary": "Privia Health, in collaboration with Amalgam Rx Inc. and Exact Sciences Corp., successfully increased colorectal cancer screening rates to 84% in 2024 through a program integrating electronic health record workflows and automated patient outreach. The initiative, which utilized Exact Sciences’ Cologuard test, engaged over 100,000 patients nationally and identified more than 550 individuals requiring diagnostic follow-up. This program demonstrates the effectiveness of technology in proactive prev", "sentiment_score": 0.402016, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Mackenzie Financial Corp Has $150.11 Million Stake in Exact Sciences Corporation $EXAS", "url": "https://www.marketbeat.com/instant-alerts/filing-mackenzie-financial-corp-has-15011-million-stake-in-exact-sciences-corporation-exas-2026-03-12/", "date": "2026-03-12", "summary": "Mackenzie Financial Corp recently decreased its stake in Exact Sciences Corporation by 3.9%, now holding 2,743,819 shares valued at $150.11 million. Several other institutional investors have also adjusted their holdings. Analysts currently have a \"Reduce\" consensus rating for Exact Sciences, with an average target price of $92.13, despite the company missing its last quarterly EPS estimates while revenue grew by 23.1%.", "sentiment_score": -0.220914, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Exact Sciences EHR Outreach Program Highlights Cologuard Growth And Valuation Debate", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/exact-sciences-ehr-outreach-program-highlights-cologuard-gro", "date": "2026-03-07", "summary": "Exact Sciences, in collaboration with Amalgam Rx and Privia Health, launched a nationwide EHR-enabled outreach program for colorectal cancer screening using its Cologuard test. This initiative has shown improved screening rates and reduced staff workload by automating patient processes. The article highlights how this integration into large-scale healthcare workflows could drive Cologuard adoption, but notes that Exact Sciences still faces significant execution risk due to its high P/E ratio and", "sentiment_score": 0.265358, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover", "url": "https://stocktwits.com/news-articles/markets/equity/exact-sciences-stock-falls-premarket-despite-wall-street-calling-for-a-triple-digit-abbott-takeover/cLPAO1VRE9V", "date": "2026-03-05", "summary": "Exact Sciences stock declined premarket despite William Blair's assertion that a potential Abbott Laboratories takeover would likely require a share price exceeding $100. This comes as Abbott is reportedly exploring a major acquisition to expand its diagnostics business, and William Blair maintained \"Outperform\" ratings on both companies. Exact Sciences' Cologuard is a key asset, and Stocktwits users are pushing for a higher bidding war, suggesting a price of $25-30 billion.", "sentiment_score": 0.137501, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration", "url": "https://www.biospace.com/press-releases/marking-national-colorectal-cancer-awareness-month-privia-health-program-achieves-84-colorectal-cancer-screening-rate-through-industry-collaboration", "date": "2026-03-04", "summary": "Amalgam Rx, Privia Health, and Exact Sciences Corp. announced a successful colorectal cancer (CRC) screening program that achieved an 84% screening rate, surpassing national benchmarks. This program, which uses EHR-integrated workflows and proactive patient outreach with Exact Sciences’ Cologuard test, highlights the importance of scalable, data-driven approaches in closing screening gaps. The initiative engaged over 42,000 patients, processed 23,000 screening orders, and identified more than 55", "sentiment_score": 0.479947, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "alpha_vantage", "title": "Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year", "url": "https://www.businesswire.com/news/home/20260304031316/en/Exact-Sciences-Named-Gallup-Exceptional-Workplace-Award-Winner-for-Third-Consecutive-Year", "date": "2026-03-04", "summary": "Exact Sciences has been recognized with the Gallup Exceptional Workplace Award for the third consecutive year, a testament to its strong and engaging workplace culture. This award highlights the company's commitment to employee wellbeing, development, and a purpose-driven environment, contributing to its continued success and positive impact on cancer care. Their consistent recognition underscores a sustained effort to foster high employee engagement and a supportive professional atmosphere.", "sentiment_score": 0.813341, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.834, "confidence": 0.83 } }, { "source": "alpha_vantage", "title": "Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld", "url": "https://www.stocktitan.net/sec-filings/EXAS/form-4-exact-sciences-corp-insider-trading-activity-37ae5873347f.html", "date": "2026-03-04", "summary": "Exact Sciences' EVP of Human Resources, Sarah Condella, exercised 3,900 stock options at $5.03 per share. To cover tax obligations, 1,913 shares were withheld by Exact Sciences at a value of $103.38 per share. Following these transactions, Condella now directly holds 131,121 shares and indirectly holds 6,368 shares in a 401(k) plan, with additional vested and unvested options and RSUs.", "sentiment_score": 0.051825, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "CSLLY or EXAS: Which Is the Better Value Stock Right Now?", "url": "https://ca.finance.yahoo.com/news/cslly-exas-better-value-stock-164002500.html", "date": "2026-03-04", "summary": "This article compares CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS) to determine which offers better value. Utilizing Zacks Rank and Style Scores, it concludes that CSLLY is the superior value option due to its #2 (Buy) Zacks Rank, improving earnings outlook, and more favorable valuation metrics like P/E, PEG, and P/B ratios compared to EXAS.", "sentiment_score": -0.139554, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.649, "confidence": 0.65 } }, { "source": "alpha_vantage", "title": "Why Gallup keeps honoring this cancer test maker’s workplace", "url": "https://www.stocktitan.net/news/EXAS/exact-sciences-named-gallup-exceptional-workplace-award-winner-for-m539wblp2yg3.html", "date": "2026-03-04", "summary": "Exact Sciences Corp. has received the 2026 Gallup Exceptional Workplace Award for the third consecutive year, recognizing its highly engaged workplace culture. The company is honored for valuing employees and connecting them to its mission of fighting cancer, leading to strong performance. Gallup's research indicates that engaged organizations like Exact Sciences show improved customer ratings, profitability, productivity, and employee well-being.", "sentiment_score": 0.467539, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.45, "confidence": 0.45 } }, { "source": "alpha_vantage", "title": "EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum", "url": "https://www.chartmill.com/news/EXAS/Chartmill-43513-EXACT-SCIENCES-CORP-NASDAQEXAS-Shows-Strong-Technical-and-Fundamental-Momentum", "date": "2026-03-04", "summary": "EXACT SCIENCES CORP (NASDAQ:EXAS) has been identified through a screening method combining technical and fundamental analysis, based on Mark Minervini's SEPA strategy. The company demonstrates strong technical characteristics, including being in a confirmed Stage 2 uptrend with specific moving average arrangements and high relative strength. Fundamentally, EXAS shows robust earnings growth, firm sales, and improving free cash flow, providing a strong basis for its price momentum.", "sentiment_score": 0.892686, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year", "url": "https://finance.yahoo.com/news/exact-sciences-named-gallup-exceptional-140000173.html", "date": "2026-03-03", "summary": "Exact Sciences has received the Gallup Exceptional Workplace Award (GEWA) for the third consecutive year, recognizing its highly engaged workplace culture. The company, a leading provider of cancer screening and diagnostic tests, was honored for fostering an environment where employees feel valued and connected to its mission, leading to strong performance. This award highlights the company's commitment to its workforce and their role in advancing the fight against cancer.", "sentiment_score": 0.482633, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.834, "confidence": 0.83 } }, { "source": "alpha_vantage", "title": "AI outreach helps engage 100,000 patients on at-home colon cancer screening", "url": "https://www.stocktitan.net/news/EXAS/marking-national-colorectal-cancer-awareness-month-privia-health-2fneeus96xn4.html", "date": "2026-03-03", "summary": "Amalgam Rx, Privia Health, and Exact Sciences collaborated on an AI-powered program that significantly increased colorectal cancer screening rates to 84% in 2024 through EHR-enabled patient outreach. The program engaged over 100,000 patients nationally, processed approximately 23,000 screening orders with minimal staff effort, and identified over 550 patients requiring diagnostic follow-up. This initiative highlights the success of scalable, data-driven approaches in closing screening gaps and i", "sentiment_score": 0.436218, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C.", "url": "https://www.marketbeat.com/instant-alerts/filing-exact-sciences-corporation-exas-shares-sold-by-fox-run-management-llc-2026-03-03/", "date": "2026-03-03", "summary": "Fox Run Management L.L.C. significantly reduced its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 77.8% in Q3, selling 19,557 shares and retaining 5,581 shares valued at $305,000. Despite a 23.1% year-over-year revenue growth, Exact Sciences missed its EPS estimates, reporting -$0.21 against an expected $0.08. Analysts hold a largely neutral-to-negative outlook on the stock, with 21 \"Hold\" ratings and 1 \"Sell\" rating, giving it a consensus \"Reduce\" rating and an average target price of $9", "sentiment_score": -0.24455, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "[Form 4] EXACT SCIENCES CORP Insider Trading Activity", "url": "https://www.stocktitan.net/sec-filings/EXAS/form-4-exact-sciences-corp-insider-trading-activity-43dd93f95c0b.html", "date": "2026-02-28", "summary": "This Form 4 filing reports insider trading activity for Aaron Bloomer, EVP and CFO of Exact Sciences Corp (EXAS). Bloomer received an equity award of 28,063 restricted stock units, which will vest in four equal annual installments starting February 25, 2027. Following this transaction, Bloomer directly holds 48,768 shares of common stock and indirectly holds 417 shares in a 401(k) plan, totaling 49,185 shares, in addition to 32,458 restricted stock units.", "sentiment_score": 0.001027, "sentiment_label": "Neutral", "relevance_score": 0.339253, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "EXAS Financials: Income Statement, Balance Sheet & Cash Flow", "url": "https://www.stocktitan.net/financials/EXAS/", "date": "2026-02-27", "summary": "This article provides a comprehensive financial overview of Exact Sciences Corp (EXAS), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2025. It highlights the company's financial health signals, including profitability, growth, leverage, liquidity, cash flow, and returns, alongside annual and quarterly data. The report indicates strong revenue growth but notes negative operating and net margins, with mixed earnings quality and concerning in", "sentiment_score": 0.083302, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "December 18th Options Now Available For EXACT Sciences (EXAS)", "url": "https://www.nasdaq.com/articles/december-18th-options-now-available-exact-sciences-exas", "date": "2026-02-27", "summary": "New options contracts for EXACT Sciences (EXAS) with a December 18th, 2026 expiration are now available. These contracts offer potential opportunities for premium collection due to the long time until expiration (294 days). Specifically, a covered call strategy using the $105.00 strike price is highlighted, suggesting a potential 1.95% return if the stock is called away.", "sentiment_score": 0.142114, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41895663", "title": "Net benefit of surveillance varies by hepatocellular carcinoma risk in patients with cirrhosis.", "authors": "Patel A et al.", "journal": "JHEP reports : innovation in hepatology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895663/", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41887238", "title": "Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis.", "authors": "Younossi ZM et al.", "journal": "The lancet. Gastroenterology & hepatology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41887238/", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41886167", "title": "Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).", "authors": "Watanuki R et al.", "journal": "Breast cancer (Tokyo, Japan)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41886167/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41886058", "title": "Nanocarrier-mediated delivery of polyphenols: an emerging strategy for overcoming biological barriers in gastrointestinal cancer therapy.", "authors": "Vijayakumar S et al.", "journal": "Bioprocess and biosystems engineering", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41886058/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41879223", "title": "Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.", "authors": "Dore M et al.", "journal": "Journal of medical economics", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41879223/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41878007", "title": "Genetic constraints on protein loop evolution: out-of-frame stop codons limit Bacillus subtilis stationary-phase mutagenesis.", "authors": "Vallin C et al.", "journal": "Frontiers in molecular biosciences", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41878007/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41877310", "title": "Zero-Dalton Resolution in Nanopore Peptide Recognition.", "authors": "Afshar Bakshloo M et al.", "journal": "Analytical chemistry", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41877310/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41876939", "title": "Diosmetin as an Effective Treatment for Cisplatin-Induced Neuropathic Pain in Mice which does not Cause Hepatic or Renal Biomarker Alterations.", "authors": "Serafini PT et al.", "journal": "Molecular neurobiology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876939/", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41867572", "title": "Natural Maghemite Nanoparticles in Crude Oil Seen by Electron Paramagnetic Resonance.", "authors": "Pessoa MS et al.", "journal": "ACS omega", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41867572/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41864395", "title": "Unmodified calcium alginate beads from Sargassum muticum brown algae: A high-capacity, reusable adsorbent for methylene blue with mechanistic insights.", "authors": "Ferroudj H et al.", "journal": "International journal of biological macromolecules", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864395/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41864383", "title": "Two thermostable and halotolerant recombinant β-glucosidases from Thermothelomyces thermophilus and their role in lignocellulosic biomass saccharification.", "authors": "da Rocha Fortes Saraiva AL et al.", "journal": "International journal of biological macromolecules", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864383/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41864341", "title": "A dynamic duo: Copper metalloregulators and continuous-wave electron spin resonance spectroscopy.", "authors": "Mandato A et al.", "journal": "Biophysical reports", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864341/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41864057", "title": "Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.", "authors": "Corti C et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864057/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41863557", "title": "Carbohydrate-Rich Extract from Pereskia aculeata Leaves: In Vitro Prebiotic-Related Properties and Metabolic Effects in an Experimental Model of Obesity.", "authors": "de Bessa ME et al.", "journal": "Plant foods for human nutrition (Dordrecht, Netherlands)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41863557/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41861615", "title": "Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.", "authors": "Ledermann JA et al.", "journal": "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41861615/", "sentiment": { "label": "negative", "score": -0.784, "confidence": 0.78 } }, { "source": "pubmed", "pmid": "41861516", "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.", "authors": "Lee P et al.", "journal": "EBioMedicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41861430", "title": "Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.", "authors": "Borkar SR et al.", "journal": "Gynecologic oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861430/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41855489", "title": "Scan, Screen, Support-A Digital Pathway for Assessing Supportive Care Needs in Oncology: Implementation Study.", "authors": "Fey T et al.", "journal": "JMIR cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41855489/", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41854792", "title": "Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.", "authors": "Masuda N et al.", "journal": "Breast cancer research and treatment", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41854792/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41854611", "title": "Neighborhood Disadvantage and Access to Liver Transplant Referral for Severe Alcohol-Associated Hepatitis.", "authors": "Nephew LD et al.", "journal": "JAMA network open", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41854611/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851476", "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "authors": "Shore ND et al.", "journal": "Prostate cancer and prostatic diseases", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851476/", "sentiment": { "label": "negative", "score": -0.751, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41843049", "title": "Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.", "authors": "Khozin S et al.", "journal": "Advances in therapy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843049/", "sentiment": { "label": "positive", "score": 0.186, "confidence": 0.19 } }, { "source": "pubmed", "pmid": "41840743", "title": "Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care.", "authors": "Samur S et al.", "journal": "BMJ open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41840743/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41838915", "title": "Lethal toxin-equipped effector cells for the potential treatment of cancer.", "authors": "Pearlman AH et al.", "journal": "Proceedings of the National Academy of Sciences of the United States of America", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41838915/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41838845", "title": "Isoselenocyanates with Sterically Encumbered Substituents─Synthesis, Structures, and Spectroscopic Properties.", "authors": "Schwade VD et al.", "journal": "Inorganic chemistry", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41838845/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41837268", "title": "Endoscopic mesorectal dissection for precise pathologic staging and potential treatment of locally advanced rectal cancer.", "authors": "Jain V et al.", "journal": "VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41837268/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41835553", "title": "Engineering a Stable Grb2 Monomer: The W60A Mutation Disrupts Dimerization but Preserves Structural Integrity.", "authors": "Tedesco JA et al.", "journal": "ACS omega", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41835553/", "sentiment": { "label": "positive", "score": 0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41835457", "title": "PDE1B and PDE10A as novel targets for schizophrenia: from molecular design and synthesis to therapeutic promise.", "authors": "Rautela J et al.", "journal": "Frontiers in pharmacology", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41835457/", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41834360", "title": "Molecular Methods for Rare Hemoglobinopathy Cases: First Brazilian Report of Pediatric Siblings with Hb O-Arab and Alpha-Thalassemia.", "authors": "Muynarsk ESM et al.", "journal": "Pediatric blood & cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41834360/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41833158", "title": "Anthropogenic forcing of gully sidewall erosion: balancing natural susceptibility and land use management in areas with Cuestas relief under tropical climate dynamics in southeastern Brazil.", "authors": "Stefanuto EB et al.", "journal": "Journal of environmental management", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41833158/", "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "pubmed", "pmid": "41831477", "title": "The challenge of defining metabolic dysfunction and alcohol-associated liver disease.", "authors": "Lian LY et al.", "journal": "The lancet. Gastroenterology & hepatology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41831477/", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41831431", "title": "Hepatocellular carcinoma: Clinical trials to watch.", "authors": "Hsiehchen D et al.", "journal": "Med (New York, N.Y.)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41831431/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41830539", "title": "GABAergic Modulation and Neurobehavioral Effects of Arjunolic Acid, a Pentacyclic Triterpene Isolated From Combretum Mellifluum Eichler: In Vivo and Molecular Docking Evaluation.", "authors": "Freitas YJDS et al.", "journal": "Chemistry & biodiversity", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41830539/", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41830538", "title": "Integrated Morphological, Molecular, and Chemical Characterization of the Macrofungus Pholiota Gallica With Phylogenetic Analysis and in Silico Antioxidant and Anti-Inflammatory Evaluation.", "authors": "Zatout R et al.", "journal": "Chemistry & biodiversity", "date": "2026-03-28", "url": "https://pubmed.ncbi.nlm.nih.gov/41830538/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41830435", "title": "Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer.", "authors": "Kiyohara H et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41830435/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41829803", "title": "Seed Nanopriming with Spirulina-Derived Carbon Dots Enhances Rice (Oryza sativa L.) Germination, Crop Establishment, and Seedling Metabolic Performance.", "authors": "Minello LVP et al.", "journal": "Plants (Basel, Switzerland)", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41829803/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41829739", "title": "Phytochemical Profiling and Antioxidant Properties of Ziziphus lotus (L.) Fruits Supported by Xanthine Oxidase Inhibition and Molecular Docking.", "authors": "Benkahoul M et al.", "journal": "Plants (Basel, Switzerland)", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41829739/", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41829649", "title": "Assessing Time-Frequency Analysis Methods for Non-Stationary EMG Bursts: Application to an Animal Model of Parkinson's Disease.", "authors": "Farfán FD et al.", "journal": "Sensors (Basel, Switzerland)", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41829649/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41829140", "title": "Assessment of IAS and NIAS in Plasma-Treated Biopolymer Films: Implications for Food Packaging Safety and Quality.", "authors": "Pereira JF et al.", "journal": "Foods (Basel, Switzerland)", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41829140/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41828850", "title": "Phytochemistry and In Vitro Bioactivities of Elaeagnus angustifolia L. Leaves: Influence of Solvent Polarity, Antioxidant Properties, and α-Amylase Inhibition.", "authors": "Bouaita R et al.", "journal": "Molecules (Basel, Switzerland)", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41828850/", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41828794", "title": "Quantitative Analysis of Bisphenol A in Commercial Beverages.", "authors": "Freitas AI et al.", "journal": "Molecules (Basel, Switzerland)", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41828794/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41828160", "title": "Novel Ternary Biopolymer Films Incorporating Amygdalin: FTIR, TG, and In Vitro Evaluation on Model Bacteria.", "authors": "Okolišan D et al.", "journal": "Materials (Basel, Switzerland)", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41828160/", "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41827784", "title": "Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France.", "authors": "Meynard G et al.", "journal": "Cancers", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41827784/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41826432", "title": "Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.", "authors": "Tarantino P et al.", "journal": "NPJ precision oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41826432/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41824209", "title": "Integrating Generative AI into Nomograms for Breast Cancer Nodal Risk Predictions.", "authors": "Shah A et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41824209/", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "pubmed", "pmid": "41824111", "title": "Sex-dependent behavioral and hypothalamic receptor changes after early-life monosodium glutamate (MSG) exposure and adult social stress in Wistar rats.", "authors": "Jung JTK et al.", "journal": "Metabolic brain disease", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41824111/", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41820395", "title": "ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.", "authors": "Collier AE et al.", "journal": "Nature communications", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820395/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41812029", "title": "A Versatile Single-Step Micro- to Nanoparticles Laser Graphitization-Driven Conversion Route for Graphene-Embedded Nanoparticle Composites.", "authors": "Eran A et al.", "journal": "ACS applied materials & interfaces", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41812029/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "edgar_news", "title": "Exact Sciences Corp", "text": "Exact Sciences Corporation entered into a merger agreement with Abbott Laboratories for $21B, resulting in Exact becoming a wholly-owned subsidiary, with changes to the rights of security holders and delisting of common stock.\n\n*Exact Sciences Corp [EXAS](https://www.google.com/finance/quote/EXAS:NASDAQ) is headquartered in Madison, WI.*\n\n[Source](https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/d128802d8k.htm)", "author": "edgar_news_01", "score": 1, "num_comments": 0, "date": "2026-03-23", "url": "https://reddit.com/r/edgar_news/comments/1s1h0xw/exact_sciences_corp/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "edgar_news", "title": "Exact Sciences Corp", "text": "Exact Sciences Corporation received all regulatory approvals for the merger with Abbott Laboratories. The merger, approved by stockholders, is expected to close on March 23, 2026, contingent on remaining conditions.\n\n*Exact Sciences Corp [EXAS](https://www.google.com/finance/quote/EXAS:NASDAQ) is headquartered in Madison, WI.*\n\n[Source](https://www.sec.gov/Archives/edgar/data/1124140/000119312526116862/d92966d8k.htm)", "author": "edgar_news_01", "score": 2, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/edgar_news/comments/1rywdzz/exact_sciences_corp/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Exact Sciences - 20 Mar 2026 @ 15:52 -> USD104.94", "text": "Ticker: **EXAS**\n\nExchange: **NASDAQ**\n\nTime: **20 Mar 2026 @ 15:52**\n\nPrice: **USD104.94**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/EXAS/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/getagraph/comments/1rz6fiy/buy_signal_exact_sciences_20_mar_2026_1552/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Wiseek", "title": "🚨 EXAS: Exact Sciences Secures All Regulatory Approvals for Abbott Merger, Anticipates March 23 Close", "text": "### New Filing: 8-K\n\n**Ticker:** EXAS | **Score:** 9/10 | **Sentiment:** Positive\n\n---\n\n### Summary (Wiseek AI)\nExact Sciences announced it has received all necessary regulatory approvals for its merger with Abbott Laboratories, with the transaction now expected to close on March 23, 2026.\n\n---\n**Further Research:**\n🤖 [**Wiseek AI Analysis**](https://wiseek.ai/ticker/exas/exact-sciences-secures-all-regulatory-approvals-for-abbott-merger-anticipates-march-23-close-000119312526116862/) | 🏛️ [**Ori", "author": "wiseeksecfiles", "score": 1, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/Wiseek/comments/1ryvz4y/exas_exact_sciences_secures_all_regulatory/", "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Exact Sciences - 19 Mar 2026 @ 15:12 -> USD103.57", "text": "Ticker: **EXAS**\n\nExchange: **NASDAQ**\n\nTime: **19 Mar 2026 @ 15:12**\n\nPrice: **USD103.57**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/EXAS/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-19", "url": "https://reddit.com/r/getagraph/comments/1ry9lxd/buy_signal_exact_sciences_19_mar_2026_1512/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Exact Sciences - 18 Mar 2026 @ 14:12 -> USD103.84", "text": "Ticker: **EXAS**\n\nExchange: **NASDAQ**\n\nTime: **18 Mar 2026 @ 14:12**\n\nPrice: **USD103.84**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/EXAS/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-18", "url": "https://reddit.com/r/getagraph/comments/1rxbkou/buy_signal_exact_sciences_18_mar_2026_1412/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Exact Sciences - 13 Mar 2026 @ 11:21 -> USD103.50", "text": "Ticker: **EXAS**\n\nExchange: **NASDAQ**\n\nTime: **13 Mar 2026 @ 11:21**\n\nPrice: **USD103.50**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/EXAS/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-03-13", "url": "https://reddit.com/r/getagraph/comments/1rsqb1i/buy_signal_exact_sciences_13_mar_2026_1121/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "getagraph", "title": "Buy Signal Exact Sciences - 26 Feb 2026 @ 12:04 -> USD103.24", "text": "Ticker: **EXAS**\n\nExchange: **NASDAQ**\n\nTime: **26 Feb 2026 @ 12:04**\n\nPrice: **USD103.24**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/EXAS/ENG", "author": "jvc72", "score": 1, "num_comments": 0, "date": "2026-02-26", "url": "https://reddit.com/r/getagraph/comments/1rffuri/buy_signal_exact_sciences_26_feb_2026_1204/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BeAmazed", "title": "Photographer François Brunelle spent 20 years documenting unrelated strangers who look exactly like twins.", "text": "", "author": "GlitteringHotel8383", "score": 59776, "num_comments": 1631, "date": "2026-03-18", "url": "https://reddit.com/r/BeAmazed/comments/1rxdzlh/photographer_françois_brunelle_spent_20_years/", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "reddit", "subreddit": "interestingasfuck", "title": "Here's what YouTube looked like in 2006 exactly 19 years ago", "text": "", "author": "7evenDeadlySin", "score": 55515, "num_comments": 1967, "date": "2026-03-07", "url": "https://reddit.com/r/interestingasfuck/comments/1rmvuit/heres_what_youtube_looked_like_in_2006_exactly_19/", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "reddit", "subreddit": "Fauxmoi", "title": "Trump: If Iran doesn’t FULLY OPEN, WITHOUT THREAT, the Strait of Hormuz, within 48 HOURS from this exact point in time, the United States of America will hit and obliterate their various POWER PLANTS, STARTING WITH THE BIGGEST ONE FIRST! Thank you for your attention to this matter. President DONALD", "text": "", "author": "fillinggoodman", "score": 19477, "num_comments": 1658, "date": "2026-03-22", "url": "https://reddit.com/r/Fauxmoi/comments/1s07dzb/trump_if_iran_doesnt_fully_open_without_threat/", "sentiment": { "label": "positive", "score": 0.724, "confidence": 0.72 } }, { "source": "reddit", "subreddit": "pcmasterrace", "title": "DLSS 5: Finally, a technology that renders exactly what the developers didn't intend.", "text": "", "author": "CeilloNoll", "score": 28742, "num_comments": 1181, "date": "2026-03-16", "url": "https://reddit.com/r/pcmasterrace/comments/1rvljdt/dlss_5_finally_a_technology_that_renders_exactly/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "What", "title": "Exactly what am I supposed to use this rope for then?", "text": "I guess it's only OK for tying up barges or skipping? Zoom in to instructions for use! ", "author": "0rlan", "score": 11125, "num_comments": 2325, "date": "2026-03-23", "url": "https://reddit.com/r/What/comments/1s1oy33/exactly_what_am_i_supposed_to_use_this_rope_for/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "gaming", "title": "Marathon sold just 1.2 million copies with nearly 70% on Steam, analyst estimates: \"It hasn't exactly made the splash Sony and Bungie wanted\"", "text": "", "author": "Freki666", "score": 8202, "num_comments": 2670, "date": "2026-03-25", "url": "https://reddit.com/r/gaming/comments/1s3478t/marathon_sold_just_12_million_copies_with_nearly/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "nba", "title": "Doris Burke after Anthony Edwards gets called for the push off: \"I'm gonna be honest with you. Oklahoma City fans are going to start hating on me right now. How many times does Shai get away with that exact kind of [play].\"", "text": "", "author": "AncientOneAurelius", "score": 16073, "num_comments": 1562, "date": "2026-03-01", "url": "https://reddit.com/r/nba/comments/1rib6yh/doris_burke_after_anthony_edwards_gets_called_for/", "sentiment": { "label": "positive", "score": 0.275, "confidence": 0.27 } }, { "source": "reddit", "subreddit": "TopCharacterTropes", "title": "Villains that were defeated by being given exactly what they wanted", "text": "Jafar (Aladdin) wished to become a genie. He got just that, but regretted it as soon as he saw that it also meant he would be forever trapped inside the lamp of one\n\nPo handed his chi to Kai (Kung Fu Panda 3) on a silver platter. The latter realized too late that the former possessed far too much chi for him to contain, causing him to literally explode.", "author": "Watchdog_the_God", "score": 15860, "num_comments": 1372, "date": "2026-03-04", "url": "https://reddit.com/r/TopCharacterTropes/comments/1rkt5lc/villains_that_were_defeated_by_being_given/", "sentiment": { "label": "negative", "score": -0.818, "confidence": 0.82 } }, { "source": "reddit", "subreddit": "shittymoviedetails", "title": "In Reign of Fire (2002) dragons awaken and emerge from underground, procreate, and almost wipe out all of humanity………..uh guys, did you not have fighter jets, warships, tanks etc. these aren’t magical Smaug dragons, there just flying reptiles that breathe fire. How exactly did we lose?", "text": "", "author": "Arcade-Blaster", "score": 10605, "num_comments": 1192, "date": "2026-03-24", "url": "https://reddit.com/r/shittymoviedetails/comments/1s2912e/in_reign_of_fire_2002_dragons_awaken_and_emerge/", "sentiment": { "label": "negative", "score": -0.815, "confidence": 0.81 } }, { "source": "reddit", "subreddit": "animalsdoingstuff", "title": "The dog on the leash is proving exactly why he’s on a leash", "text": "", "author": "Brilliantspirit33", "score": 11146, "num_comments": 841, "date": "2026-03-21", "url": "https://reddit.com/r/animalsdoingstuff/comments/1rzvznr/the_dog_on_the_leash_is_proving_exactly_why_hes/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "animalsdoingstuff", "title": "The way it receives the red fruit, lightly tosses it, and then picks it up again is exactly like a human movement. 😂", "text": "", "author": "Brilliantspirit33", "score": 17133, "num_comments": 517, "date": "2026-03-24", "url": "https://reddit.com/r/animalsdoingstuff/comments/1s2ss4y/the_way_it_receives_the_red_fruit_lightly_tosses/", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "reddit", "subreddit": "interviews", "title": "Interviewer asked me a question with no right answer and then explained exactly why he does it - actually changed how I think about interviews", "text": "Had a first round yesterday for a mid-level project manager role. The interviewer was the hiring manager himself, which I wasn't expecting for a first round, but fine.\n\nFirst 20 minutes were pretty standard. Walk me through your experience, tell me about a challenging project, the usual. And then he pauses and goes \"okay I'm going to ask you something a bit different now.\"\n\nThe question was: \"If you had to choose between delivering a project on time with known quality issues, or delivering it la", "author": "SaffronGadget", "score": 8442, "num_comments": 823, "date": "2026-03-16", "url": "https://reddit.com/r/interviews/comments/1rvkcwo/interviewer_asked_me_a_question_with_no_right/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "reddit", "subreddit": "todayilearned", "title": "TIL that Conan O’Brien, David Letterman and Jay Leno all once made the same Dan Quayle joke on the same night without any knowledge of the others making the same exact joke.", "text": "", "author": "RareXG", "score": 16675, "num_comments": 509, "date": "2026-03-18", "url": "https://reddit.com/r/todayilearned/comments/1rxbwef/til_that_conan_obrien_david_letterman_and_jay/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "mildlyinteresting", "title": "My tank filled for exactly $100.00", "text": "", "author": "lionstigersbearsomar", "score": 8298, "num_comments": 709, "date": "2026-03-26", "url": "https://reddit.com/r/mildlyinteresting/comments/1s40xdr/my_tank_filled_for_exactly_10000/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "whoathatsinteresting", "title": "A video of a Russian woman being beaten in Thailand has surfaced online - the footage shows her attacking first. The exact date the video was filmed is still unknown.", "text": "", "author": "eternviking", "score": 5114, "num_comments": 1342, "date": "2026-03-20", "url": "https://reddit.com/r/whoathatsinteresting/comments/1ryqpcq/a_video_of_a_russian_woman_being_beaten_in/", "sentiment": { "label": "negative", "score": -0.7, "confidence": 0.7 } } ] } }